Express Pharma

Dr Bhaskar Chaudhuri and Alan Rosling join Vyome Biosciences’ board of directors

8

Chaudhuri is the operating partner of Frazier Healthcare Ventures and Rosling is the senior advisor at Navam Capital

Vyome Biosciences, a clinical stage dermatology based biopharmaceutical company, has appointed Dr Bhaskar Chaudhuri and Alan Rosling to its Board of Directors.

Reportedly, Chaudhuri has more than 25 years of experience with leading biopharma companies in leadership, strategy and management, drug research and development, and commercialisation in the US, EU and emerging markets. He has led the development and FDA approval of multiple New Drug Applications (NDAs). Chaudhuri served as the President and Chief Executive Officer of Dow Pharmaceuticals for seven years, leading up to their acquisition by Valeant Pharmaceuticals. After acquisition, Chaudhuri served as the President of Valeant Pharmaceuticals International from January 2009 till September 2010. He is currently an Operating Partner of Frazier Healthcare Ventures. Chaudhuri has a doctorate in physical pharmacy.

“As Vyome scales up multiple drug development programmes, enters clinical trials and accelerates the commercialisation phase, Chaudhuri will add tremendous strategic experience to the Board. His vast experience in commercialising novel dermatology drugs, and leadership with top-tier pharma companies will brings significant value to Vyome,” said Venkateswarlu Nelabhotla, Co-founder and Chief Executive Officer, Vyome Biosciences.

“Vyome is a proving to be a highly credible innovative player in the life sciences industry, with novel platforms and drug development programmes, and I am delighted to be a part of the company’s illustrious Board of Directors. Vyome’s current portfolio of innovative and breakthrough products provides a strong foundation for the company to emerge as a global leader in its field,” Dr Chaudhuri added.

Alan Rosling is the senior advisor at Navam Capital. Rosling co-founded Kiran Energy in 2010 and was the Executive Director of Tata Sons and Chairman of the Jardine Matheson Group in India.

“I am delighted that Chaudhuri is getting involved with Vyome at this crucial stage of commercialisation. He has a stellar reputation as a business strategist, and his extensive experience in the biopharma industry will be a valuable asset for the company. Alan Rosling brings strong global business experience to the Board, and he will be a tremendous resource for the company as it continues to go from strength to strength in the coming years,” commented Dr Raghunath Mashelkar, Chairman of Vyome’s Board of Directors.

EP News BureauMumbai

Comments are closed.